Recent News

• 10.22.2025 - CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
• 10.14.2025 - CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
• 10.02.2025 - CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
• 08.28.2025 - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
• 08.19.2025 - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
• 07.21.2025 - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

Recent Filings

• 10.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.22.2025 - EX-99.1 EX-99.1
• 10.14.2025 - EX-99.1 EX-99.1
• 10.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.02.2025 - EX-99.1 EX-99.1
• 09.30.2025 - EX-99.1 EX-99.1
• 09.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.22.2025 - 144 Report of proposed sale of securities
• 08.28.2025 - EX-99.1 EX-99.1